Skip to main content

Table 2 Treatment response

From: CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial

 CEOP/IVE/GDP (N = 51) *CEOP (N = 51) *p value
Response at interim
 Complete response17 (33.3%)18 (35.3%)0.834
 Partial response26 (51.0%)13 (25.5%)0.008
 Stable disease4 (7.8%)7 (13.7%) 
 Disease progression3 (5.9%)11 (21.6%) 
 Overall response43 (84.3%)31 (60.8%)0.008
Response at EOT
 Complete response19 (37.3%)16 (31.4%)0.532
 Partial response18 (35.3%)9 (17.6%)0.042
 Stable disease4 (7.8%)7 (13.7%) 
 Disease progression9 (17.6%)17 (33.3%) 
 Overall response37 (72.5%)25 (49. 0%)0.015
  1. EOT end of treatment
  2. *One patient in the CEOP/IVE/GDP group could not be evaluated due to toxicity (n = 1). Two patients in the CEOP group could not be evaluated due to toxicity (n = 1) and consent withdrawal (n = 1). All the three patients were considered as no responders from statistically conservative consideration